Table 1.
Anticancer fingerprints of Lwk-n019 based on NCI-investigated drugs
| Correlation | CCLC | Target NSC | Target descriptor | |
|---|---|---|---|---|
| 0.42 | 57 | 818434 | LOXO-292 | RET inhibitor |
| 0.42 | 57 | 759224 | IDELALISIB | PI3K inhibitor |
| 0.4 | 57 | 811429 | CT-BLU667 | RET inhibitor |
| 0.39 | 57 | 789102 | IVOSIDENIB | Anti-leukemia |
| 0.39 | 57 | 775772 | GLASDEGIB | Anti-leukemia |
| 0.38 | 58 | 772469 | INK-1197 | PI3K |
| 0.36 | 56 | 760766 | VANDETANIB | TKI |
| 0.35 | 58 | 789300 | Pexidartinib (PLX3397) | FLT3 inhibitor |
| 0.34 | 58 | 141540 | VP-16 (etoposide) | Top II |
| 0.12 | 58 | 125066 | bleomycin | Anti-leukemia |
| 0.12 | 57 | 122819 | VM-26 (teniposide) | TOP II |
| 0.12 | 57 | 609699 | topotecan | TOP1 |
CCLC, Common Cell Line Count; Correlation, Pearson’s Correlation Coefficient.